Toll-like receptors (TLRs) are considered as potential targets for vaccine adjuvants. Here, we explored the impact of TLR agonists on the B cell response to a prototypic thymus-independent (TI) antigen: a Streptococcus pneumoniae capsular polysaccharide (PS). In adult mice, all TLR agonists (and CpG oligodeoxynucleotides [ODN] in particular) enhance the PS antibody response, provided that their administration is delayed until the second day after PS vaccination. In infant mice, CpG ODN not only potentiated the PS3 antibody response but also restored responsiveness to PS3 vaccination. Moreover, the immune protection induced by the plain PS3 vaccine adjuvanted by CpG ODN was comparable to that conferred by the conjugate vaccine in terms of efficiency and longevity. CpG ODN exert their adjuvant effect by increasing the survival rate of antigenstimulated B cells as well as the output of plasmablasts. Our results provide a rationale for broader application of polysaccharidic vaccines.
M A J O R A R T I C L E
Infections caused by extracellular bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, or Haemophillus influenzae, represent a major cause of morbidity and mortality. Since the mid-1900s, the growing resistance of pathogenic bacteria to antibiotic therapy has raised concern that improved vaccines are needed to complement antimicrobial therapy. The humoral antibody response plays a major role in adaptive immunity against extracellular bacteria. In many cases, it is directed against polysaccharides (PS) of the bacterial cell wall or capsule, which represent prototypic thymus-independent (TI) antigens. These antigens have initially been defined on the basis of their ability to elicit an antibody response in T cell-deficient or athymic mice by a mechanism that requires expression of a functional Bruton's tyrosine kinase [1] . To overcome systemic infections by encapsulated extracellular bacteria, such as S. pneumoniae, B cells rapidly generate a protective antibody response against capsular PS. Although pneumococcal PS can elicit protective immunity [2] , vaccine development is complicated by the existence of at least 90 S. pneumoniae serotypes and their heterogeneous geographical distribution. The first pneumococcal vaccine available has been the Pneumovax (Merck), a polyvalent vaccine that is constituted of purified capsular PS from the 23 most common serotypes of S. pneumoniae, including serotype 3. Although this vaccine is protective in adults [3 , 4] , it is of limited use in children under 2 years of age and in the elderly population [5] . The unresponsiveness of young children to plain polysaccharide vaccines can be overcome by the covalent conjugation of PS to a protein carrier to generate T cell-dependent (TD) responses [6] . Delayed but not concomitant administration of Toll-like receptor (TLR) agonists enhances the TI antibody response to serotype 3 capsular Streptococcus pneumoniae polysaccharide (PS3). C57BL/6 mice were injected subcutaneously with sterile and pyrogen free phosphate-buffered saline (PBS) or 0.5 mg of PS3 diluted in PBS with or without various TLR agonists administered either simultaneously (A and B ) or 2 days after PS3 vaccination (C and D ). Serum samples and splenocytes were collected at day 5 after vaccination, and the anti-PS3 immunoglobulin (Ig) M titers (A and C ), as well as the numbers of PS3-specific total antibody secreting cells (ASCs) (B and D ) were determined by enzyme-linked immunosorbent assays (ELISAs) and enzyme-linked immunosorbent spot assays (ELISPOTs), respectively. Results are expressed as mean values ‫ע‬ the standard error of the mean for data collected for 5 individual mice. Statistical significance of differences was determined by the Kruskal-Wallis and Dunn post test. P values р.05 (*) , р.01 (**), or р.001 (***) were considered to be statistically significant.
However, conjugate vaccines present 2 drawbacks. First, they have a more restricted serotype coverage than do plain PS vaccines (7 for Prevnar vs 23 for Pneumovax). Second, their relatively high costs of production are a barrier to their widespread introduction. Therefore, improvement of the existing PS vaccines is an important public health issue. Toll-like receptors (TLRs) are pattern recognition receptors that play a central role as sensors of infection and inducers of innate and adaptive immune responses [7] and are therefore considered as potential targets for vaccine adjuvants. Although the adjuvant effect of TLR agonists, such as CpG oligodeoxynucleotides (ODN) for TD antigens and for the TD form (PSprotein conjugates) of PS, in particular, is uncontested [8] [9] [10] , contradictory results have been published concerning the potential adjuvant effect of TLR agonists on TI antibody responses. Kovarick et al [11] demonstrated that, whereas CpG ODN significantly enhance antigen-specific immunoglobulin (Ig) M and IgG responses to trinitrophenylated Ficoll, they fail to increase Ig titers in response to any of the 18 PS serotypes from S. pneumoniae tested, either in adult or young mice. By contrast, upon co-administration, the TLR4 agonist monophosphoryl lipid A has been shown to enhance the antibody response to Pneumovax in adult and aged mice [12] .
In the present study, we demonstrate that TLR agonists (and CpG ODN in particular) can boost the primary antibody response induced by a serotype 3 S. pneumoniae capsular PS both in adult and young mice, provided that they are administered 2 days after vaccination. We also show that the humoral immunity induced by a single immunization with the plain PS vaccine adjuvanted with CpG ODN is comparable, in terms of efficiency and longevity, to that conferred by a prime/boost immunization with the conjugate vaccine. Finally, we bring evidence that CpG ODN exert their adjuvant effect on the PSspecific antibody response by increasing the survival rate of antigen-stimulated B cells, as well as the output of plasmablasts.
METHODS

Mice and vaccinations.
Three-to 15-week-old C57BL/6J mice were purchased from Charles River Laboratories and maintained in pathogen-free conditions at the Plateau de Biologie Expéri-mentale de la Souris (Ecole Normale Supérieure de Lyon; Lyon, 2 ϫ 10 medium 1640 containing 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, 100 mM streptomycin, 2% HEPES, and freshly added 50 mM 2-mercapto-ethanol (all from Invitrogen Life Technologies). Mononuclear cells were activated with NP-dextran at 0.5 ng/mL (Biosearch Technologies) alone or in the presence of CpG1668 added 2 days later. The cells were harvested on day 3 and stained with anti-CD19-PerCP-Cy5.5 (clone: 1D3), anti-CD138-PE (clone: 281-2), annexin V-PE or anti-CXCR4-biotin (clone: 2B11) followed by incubation with streptavidin-PE (all from BD Biosciences). Because 95% of the splenic CD19 + B cell population from QM mice were NP-specific as determined by staining with the antiidiotypic monoclonal antibodies (17.2.25) (data not shown), we assumed that the CD19 marker was sufficient to identify the NP-specific B cell population.
S. pneumoniae infections. The encapsulated serotype 3 WU2 strain of S. pneumoniae was grown in Todd-Hewitt broth supplemented with 0.5% yeast extract to mid-log phase, then enumerated by plating the suspension on blood agar plates, and finally frozen as glycerol stocks at Ϫ80ЊC. At the time of infection, different doses of bacteria were diluted in 200 mL of sterile PBS for intraperitoneal injection. The number of colony forming units (cfu) injected was confirmed by enumerating colony growth on blood agar plates. S. pneumoniae challenges were performed in a biosafety level 2 animal facility.
Enzyme-linked immunosorbent assays (ELISAs) and enzyme-linked immunosorbent spot assays (ELISPOTs). PS3-specific antibody titers were measured by ELISAs, and PS3-specific antibody secreting cells (ASCs) were quantified by ELISPOT, as described elsewhere [15] (Appendix; online only).
Statistical analysis. Data are expressed as mean values ‫ע(‬ standard error of the mean) for individual mice. Statistical significance of differences was determined by the Kruskal-Wallis and Dunn post test, the Mann-Whitney U test, and the logrank test, as appropriate, using the GraphPad software, version 5.0. Differences with P values р.05 were considered to be statistically significant.
RESULTS
TLR agonists boost the primary antibody response to the PS3 vaccine. We previously showed that delayed administration of the TLR9 agonist CpG1668 enhances both the antibody response to PS3 and the generation of PS3-specific long-lived plasma cells in the bone marrow [15] . Here, we have investigated whether the ability to boost the antibody response elicited by a plain polysaccharidic vaccine is shared by other TLRs. To explore this point, different TLR agonists targeting TLR1/2 (Pam 3 CSK 4 ), TLR2/6 (MALP2), TLR3 (Poly I:C), TLR4 (MPL), TLR5 (flagellin), TLR7/8 (R848), or TLR9 (CpG1668) were either co-injected with PS3 or administered 2 days after PS3 vaccination of C57BL/6 mice. Mice were sacrificed on day 5 after vaccination, and serum anti-PS3 IgM titers, as well as splenic anti-PS3 ASC numbers, were quantified by ELISA and ELISPOT assays, respectively. As previously described for CpG1668, neither serum antibody titers nor ASC numbers were increased when the different TLR agonists were co-administered with the PS3 vaccine ( Figure 1A and 1B) . By contrast, all TLR agonists increased the anti-PS3 IgM titers and PS3 ASC numbers when injected 2 days after PS3 vaccination ( Figure  1C and 1D) . It is noteworthy that all TLR agonists tested failed to induce any PS3 response when administered to PBS-injected mice. Similar results were obtained with the serotype 4 S. pneumoniae capsular PS (PS4), suggesting that the adjuvant effect of TLR agonists on PS vaccines is not restricted to a single-model TI antigen (Figure 2) . The adjuvant effect of CpG1668 was not limited to the IgM response, because this TLR agonist was found to enhance the levels of IgG1, IgG2b, IgG2c, and IgG3 PS3 Ab, the latter isotype largely dominating the IgG isotype response induced by PS3 and CpG (Figure 3) .
CpG1668 increases the output of plasmablasts produced in response to TI antigens. We next explored the mechanism whereby CpG1668 exerts its adjuvant effect on the antibody response to TI antigens. The frequency of PS3-specific B cells is too low to analyze the impact of CpG ODN on the parameters of the B cell response to TI antigens. We thus switched to another polysaccharidic antigen (NP-dextran) and to a strain of mice presenting a quasi-monoclonal NP-specific B cell repertoire (QM mice). NP-dextran behaves as a bona fide TI antigen, as illustrated by its capacity to elicit an antibody response in T cell-deficient mice ( Figure 4A ). We first investigated, using WT mice, whether the characteristics of the adjuvant effect of CpG ODN that we had previously defined for PS3 were conserved for NP-dextran. C57BL/6 mice were thus vaccinated with NP-dextran and injected with CpG1668 either at the time of vaccination or 2 days later. As previously observed for PS3, delayed administration of CpG1668 was required to enhance the NP antibody response in mice vaccinated with NP-dextran ( Figure 4B ). We next investigated whether the adjuvant effect of CpG ODN on TI antibody responses could be reproduced in vitro and, if so, whether it also required uncoupling of the TLR agonist and antigen stimulations. For this purpose, cultures of peritoneal cells from WT mice were conducted with PS3 or NP-dextran and supplemented with CpG1668 either at the initiation of the culture or 2 days later. In both models, addition of CpG1668 at the onset of the culture with the TI Ϫ/Ϫ mice (5 per group) were vaccinated subcutaneously with phosphate-buffered saline (PBS) or 100 mg of NP-dextran. Serum samples were collected at day 7 after vaccination, and the anti-NP antibody titers were determined by enzymelinked immunosorbent assay (ELISA). B, C57BL/6 mice (5 per group) were injected subcutaneously with PBS or NP-dextran and injected with CpG1668 either at day 0 or at day 2 after vaccination. Serum samples were collected at day 7 after vaccination, and the anti-NP antibody titers were determined by ELISA. Peritoneal mononuclear cells from C57BL/6 mice were activated or not in vitro with PS3 (C ) or NP-dextran (D ) in the presence or absence of CpG added at day 0 or day 2 after initiation of the culture. Cells were harvested on day 5 of the culture, and frequencies of PS3-(C ) or NPspecific (D ) total antibody secreting cells (ASCs) were determined by enzyme-linked immunosorbent spot assay (ELISPOT). Results are expressed as mean values ‫ע‬ the standard error of the mean of the data collected for 3-5 individual mice. Statistical significance of differences was determined by the Kruskal-Wallis and Dunn post test. P values р.05 (*) , р.01 (**), or р.001 (***) were considered to be statistically significant.
antigen failed to significantly amplify the numbers of antigenspecific ASCs, whereas its addition on day 2 induced a 3-5-fold increase of the response ( Figure 4C and 4D) . Having demonstrated that the interplays of PS3 and NP-dextran with CpG ODN were comparable both in vivo and in vitro, we next used cultures of splenocytes from QM mice to dissect the adjuvant effect of CpG1668 on the antibody response to NP-dextran.
For this purpose, QM splenocytes were labeled with the division tracking dye CFSE and cultured with NP-dextran, CpG, or NP-dextran and CpG (the latter being added 2 days after initiation of the cultures). B cells (gated as CD19 + cells) were stained at the end of the 3-day culture with the following: CD138, to reveal plasma cell differentiation; annexin V, to estimate their survival rate; and CXCR4, to estimate the homing potential of plasma cells to the bone marrow. CpG1668 added alone for the last 24 h of the culture did not induce any cell division. By contrast, its addition to cells stimulated with NPdextran increased the numbers of antigen-activated B cells recruited to enter division, as evidenced by the reduced proportion of undivided cells ( Figure 5A ). Addition of CpG also increased the numbers of cells that have undergone 3-5 divisions ( Figure 5A and 5E ), an effect which is probably imputable to its positive impact on B cell survival ( Figure 5C ). Furthermore, in cultures stimulated with NP-dextran, CpG1668 greatly increased the numbers of cells expressing the plasma cell marker CD138 ( Figure 5B and 5F ). Finally, B cells stimulated with NPDextran and CpG1668 maintained a higher expression level of CXCR4, which is known to be involved in the homing of plasmablasts to the bone marrow, compared with B cells activated with the TI antigen alone ( Figure 5D ).
CpG1668 restores responsiveness of infant mice to the PS3 vaccine. Infant mice, like young children, are unresponsive to polysaccharidic antigens [16] . We therefore wondered whether TLR agonists could restore the humoral immune response of infant mice to the PS3 vaccine. Three-week-old mice were vaccinated either with PS3 alone or with the CpG1668-adjuvanted PS3 vaccine, and their responses were compared with those of 15-week-old mice vaccinated in the same conditions. As expected, in response to PS3 vaccination, serum PS3 antibodies ( Figure 6A ), as well as splenic PS3-specific ASCs Fifteen-week-old and 3-week-old mice were vaccinated subcutaneously with phosphate-buffered saline (PBS) or 0.5 mg of PS3 and injected 2 days later with 80 mg of CpG1668. Serum samples and splenocytes were collected at day 5 after vaccination, and the anti-PS3 immunoglobulin (Ig) M titers (A), as well as the number of PS3-specific total antibody secreting cells (ASCs) (B ) were determined by enzyme-linked immunosorbent assays (ELISAs) and enzyme-linked immunosorbent spot assays (ELISPOTs), respectively. Results are expressed as mean values ‫ע‬ the standard error of the mean of the data collected for 5 individual mice. Statistical significance of differences was determined by the Mann-Whitney U test. P values р.05 (*), р.01 (**), or р.001 (***) were considered to be statistically significant.
( Figure 6B ), were nearly undetectable in infant mice, compared with adult mice. Nevertheless, administration of CpG1668 2 days after PS3 vaccination restored the PS3 antibody response in infant mice to the level obtained after vaccination of adult mice with PS3 alone, demonstrating that the unresponsiveness of infant mice to the PS3 vaccine can be circumvented by the adjuvant effect of TLR agonists.
CpG1668 increases the efficiency of the protection conferred by the PS3 vaccine in both adult and infant mice. We next sought to determine whether the stimulatory effect of TLR agonists on the antibody response to PS3 vaccination was correlated with enhanced protection against S. pneumoniae infection. For this purpose, mice were vaccinated with the PS3 vaccine alone, the CpG1668-adjuvanted PS3 vaccine, or PS3TT and were challenged 30 days later with increasing numbers of live bacteria of the encapsulated serotype 3 strain of S. pneumoniae. The PS3TT vaccine (administered with use of the prime/ boost injection protocol) was used as our reference, because such conjugate vaccines are protective for children !2 years of age.
All vaccinated adult mice were protected against a 10 6 cfu inoculum, whereas 100% of naive and CpG-injected mice succumbed after injection of a 10 3 cfu inoculum ( Figure 7A ). Only 25% of the mice vaccinated with the plain PS3 vaccine survived the injection of 10 7 live bacteria. By contrast, all mice vaccinated with the conjugate or CpG-adjuvanted PS3 vaccine survived this inoculum of live bacteria ( Figure 7A ) but succumbed to injection of 10 8 live bacteria (data not shown). Similar experiments were conducted with infant mice that were vaccinated at 3 weeks of age. As expected, 3-week-old mice vaccinated with PS3 alone were more susceptible to S. pneumoniae infection than were adult mice, with 10 4 and 10 6 cfu causing 40% and 100% mortality, respectively ( Figure 7B ). By contrast, mice vaccinated with the CpG1668-adjuvanted PS3 Figure 7 . CpG1668 enhances the efficiency and longevity of the immunity conferred by the serotype 3 capsular Streptococcus pneumoniae polysaccharide (PS3) vaccine. Twelve-week-old (A) or 3-week-old (B ) mice received a single injection of phosphate-buffered saline (PBS) (naive mice), CpG1668, PS3 followed or not by CpG1668 injection 2 days later, or were vaccinated twice with the tetanus toxin-conjugated form of PS3 (PS3TT) with a 28 days interval. Survival of mice (8 per group) was determined 30 days after vaccination after intraperitoneal challenge with different doses of the S. pneumoniae WU2 strain. All naive or CpG1668-injected 3-week-old mice who were exposed to 10 2 colony-forming units (cfu) of S. pneumoniae died in the first 3 days after challenge (data not shown). C, Effect of CpG1668 on the longevity of the protection conferred by the PS3 vaccine. Survival of mice (8 per group) after challenge with 10 6 cfu of live WU2 bacteria was determined 90, 120, and 150 days after vaccination (ie, after the boost injection for PS3TT). The log-rank test was used to determine the statistical significance of differences. P values of !.05 (*) and !.01 (**) were considered to be statistically significant. NS: non significant.
vaccine or PS3TT exhibited a comparable increased resistance to infection by 10 6 cfu, characterized by an average survival rate of 40% ( Figure 7B) .
CpG1668 increases the longevity of the protection conferred by the PS3 vaccine. We next compared the longevity of the immune protection afforded by the 3 types of PS3 vaccines described above. Adult mice vaccinated with PS3, CpG-adjuvanted PS3, or the PS3-conjugate vaccine were exposed to a fixed dose of 10 6 live S. pneumoniae at different time points after vaccination. All vaccinated mice were equally protected at 90 days after vaccination ( Figure 7C ). However at 120 and 150 days after vaccination, the mortality rates in the group vaccinated with PS3 were 60% and 100%, respectively, whereas 100% of the mice vaccinated with the CpG1668-adjuvanted PS3 vaccine or PS3TT were still alive ( Figure 7C ). Thus, CpG ODN enhance both the efficiency and longevity of the antipneumococcal immunity conferred by the plain PS3 vaccine.
DISCUSSION
The innate immune system and natural antibodies, in particular, are key players during bacterial infections [17] . However, when the bacterial load is too high, the innate immune system is rapidly overflowed, and the ability of the adaptive humoral response to produce large amounts of antibodies directed against bacteria becomes essential. The goal of an anti-bacterial vaccine is precisely to generate memory B cells able to rapidly elicit massive secretion of bactericidal antibodies. Plain PS vaccines, can induce relatively short-lived immunity in adults [3, 4] limited to 5-10 years, compared with several decades of anamnestic responses that can be induced by protein antigens and by whole viruses [18] . In addition, plain PS are inefficient in children !2 years of age and in the elderly population [5] . Our results open new scopes for the use of plain PS vaccines for the following reasons. First, we showed that the adminis-tration of a TLR agonist to mice vaccinated with a plain PS vaccine enhances up to 10 times the primary antibody response. Second, the CpG-adjuvanted vaccine favored IgG isotype switching and, in particular, switching to IgG3, which is an isotype that has been reported to play a major role in the opsonophagocytic activity and protection towards type 3 S. pneumoniae [19] . Third, in adult mice, the efficiency and the longevity of the anti-pneumococcal immunity conferred by the CpG-adjuvanted PS3 vaccine was comparable to that obtained with the conjugate vaccine. Fourth, the CpG-adjuvanted PS3 vaccine restored a level of responsiveness of infant mice to PS3 that is comparable to that in the adults. This notion was first suggested by the in vitro data reported by Mond et al [20] , which showed that LPS enables neonatal B cells to mount an IgM response to the surrogate TI antigen, anti-Ig-dextran. However, our work is the first in vivo demonstration that a TI vaccine can be rendered as protective as its conjugate counterpart for infant mice. The reason why TLR agonists require administration 2 days after vaccination to exert their adjuvant effect on the PS antibody response remains an open question. Baker et al [21] initially reported that delayed administration of MPL after PS3 vaccination allowed for inactivation of suppressor T cells. A similar TLR-mediated release from suppression induced by CD4 + CD25 + regulatory T cells has been reported for activation of pathogen-specific T cells [22 , 23] . However, such a mechanism is unlikely to be involved in repression of the stimulatory effects of TLR agonists in the present co-administration setting. First, in agreement with a recent study [24] , we found that depletion of CD4 + CD25 + T cells modulated neither the PS3 antibody response nor the adjuvant effect of CpG1668 (data not shown) on this response. Second, the amplitude of the TLR-adjuvanted PS3 antibody response in CD3e-deficient mice was comparable to that obtained in wild-type mice [15] . This indicates that, in contrast to pathogen-specific T cell responses, the B cell response to bacterial PS is not under the control of regulatory T cells. The necessity to uncouple administration of the TLR agonist from that of the vaccine to reveal its adjuvant properties remains a major obstacle for human vaccination. Experiments are underway to explore means of circumventing this difficulty.
Having previously described that the adjuvant effect of CpG1668 in vivo is directly targeted to B cells [15] , it seemed reasonable to postulate that the same rule applied to the effect of CpG1668 on B cell proliferation and survival in vitro. This notion is in agreement with the previously reported enhancement by CpG ODN of both proliferation and survival of isolated B cells in response multivalent surrogate TI antigens [25] . Moreover, CpG ODN have been reported to protect immature B cell lines from apoptosis triggered by engagement of the BCR through upregulation of NFkB P50/c-Rel activity and maintenance of c-myc levels [26] [27] [28] . We postulate that, in our case, CpG ODN protect B cells from activation-induced cell death possibly favored by the extensive BCR cross-linking promoted by TI antigens, such as PS3.
In conclusion, we have established for a model TI antigen (PS3) that the immune protection conferred by the plain PS vaccine when it is adjuvanted with a TLR agonist is qualitatively and quantitatively equivalent to that conferred by the conjugate vaccine, generally considered to be the gold standard. Our data suggest that the features of TI vaccines that have been seen as drawbacks (ie, short-lived immune protection and unresponsiveness of young children) may be circumvented by an appropriate use of TLR agonists. Naturally, it will be crucial for future vaccine development to determine to which extent our present observation with PS3 is applicable to other bacterial TI antigens. Collectively, these findings bear potential important public health implications, because they open perspectives for a broader utilization of PS-based vaccines. For example, the possibility to substitute TLR agonist-adjuvanted plain PS vaccines for conjugate vaccines has obvious repercussions for antibacterial vaccination of children, because it should lower the vaccine costs and thus allow for a widespread introduction and because it will broaden the serotype coverage of the vaccine.
